• Vivoryon Therapeutics held its annual general meeting on Sept. 29, 2026.
• Shareholders adopted all agenda items.
• Appointment of CFO Marcus Irsfeld as an executive director was approved; the filing does not confirm completion of the appointment.
• Re-appointments of executive directors Dr. Frank Weber and Dr. Michael Schaeffer were approved; the filing does not confirm completion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vivoryon Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609291200OMX_____CNEWS_EN_GNW1001275240_en) on September 29, 2026, and is solely responsible for the information contained therein.